- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01614613
Comparison Evaluation of Blood Glucose Meter Systems in a Clinical Setting
January 29, 2016 updated by: Ascensia Diabetes Care
Clinical Evaluation of Bayer G3 / Tatsu System and BGMs From Other Companies
The purpose of this study was to test the performance of an investigational Bayer Blood Glucose (BG) meter and five additional Blood Glucose Monitoring Systems (BGMSs).
The goal was to obtain glucose samples from subjects with diabetes across the meter operating ranges.
A capillary sample was collected from each subject at 3 different times during the visit to obtain natural capillary blood samples with a range of glucose concentrations.
Some blood samples were glycolyzed to lower the glucose concentration levels and glucose solution was added to other samples to raise glucose concentration levels.
All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
All lancings and testing were performed by study staff.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Device: Bayer G3 / Tatsu System
- Device: Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips
- Device: Freestyle Lite® Meter and Test Strips with ZipwikTM tabs
- Device: OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips
- Device: One Touch® VerioTM Pro/One Touch® VerioTM Test Strips
- Device: Truetrack® Meter/Truetrack® Test Strips
Study Type
Interventional
Enrollment (Actual)
146
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Renton, Washington, United States, 98057
- Rainier Clinical Research Center Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of type 1 or type 2 diabetes mellitus
- 18 years of age or older
- Willing to follow all study procedures
Exclusion Criteria:
- Received an investigational drug or device within the last 30 days
- Current use or recent exposure to any prescription medication within 24 hours prior to screening that in the opinion of the investigator could have an influence on the subject's ability to participate in the study or on the performance on the test device
- Positive pregnancy test obtained at screening (test performed for females only, except if surgically sterile or three years past menopause)
- Hematocrit <32% or >55%
- Inadequate veins (in the opinion of the investigator or designated study staff) for venous blood withdrawal or intravenous catheter insertion
- Symptomatic coronary artery disease with a history of angina, or history of a myocardial infarction or coronary intervention (e.g. percutaneous transluminal coronary angioplasty [PTCA], stent placement) or coronary artery bypass graft (CABG) within the past 6 months
- Cerebrovascular accident within the past 6 months
- Diagnosis of the following diabetic autonomic neuropathies: symptomatic orthostatic hypotension, heart rate anomalies, gastroparesis
- Being treated for malignancy, except basal cell or squamous cell skin cancers
- Major surgical operation within 30 days prior to screening
- Active alcohol abuse or substance abuse (as judged by the principal investigator)
- Severe mental illness, mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation (as judged by principal investigator)
- Other medical conditions that would pose safety concerns, interfere with study conduct or seriously compromise study integrity, as judged by principal investigator (reason for exclusion will be clearly documented by investigator or designee)
- Working for a competitive medical device company, or having an immediate family member or someone who is not a family member but is living within the household of someone who works for such a company
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intended BGM Users
Subjects were assigned to subgroups according to their initial glucose levels.
SUBGROUP 1 goal: safely decrease subject glucose levels during the visit.
SUBGROUP 2 goal: safely raise subject glucose levels.
Also, blood samples were modified to obtain glucose concentrations across the needed glucose ranges while maintaining subject safety.
Staff tested the blood samples using the 6 Blood Glucose Monitoring Systems.
Bayer G3/Tatsu System;Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips; Freestyle Lite® Meter and Test Strips with ZipwikTM tabs;OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips;One Touch® VerioTM Pro/One Touch® VerioTM Test Strips;Truetrack® Meter/Truetrack® Test Strips
|
Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes.
All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes.
All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes.
All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes.
All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes.
All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes.
All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MAD Mean Absolute Value of the Difference Between Blood Glucose Meter (BGMS) Results and Corresponding YSI Blood Glucose (BG) Results in the Low BG Range(<70 mg/dL)
Time Frame: 6 hours
|
Using samples with BG < 70 mg/dL, the Mean Absolute Value of the Differences Between BGM system readings and the YSI laboratory reference values were compared.
MAD was calculated from the sum of all |(BG meter)-(BG reference)| assessments, divided by the number of assessments.
Each evaluable sample was tested on all 6 BGMS, thus the same number of BG test results was analyzed for each BGMS intervention.
Lower MAD value indicates smaller difference between meter value and the reference value.
Higher MAD value indicates larger difference between meter value and the reference value.
|
6 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MAD Mean Absolute Value of the Difference Between Blood Glucose Meter (BGMS) Results and Corresponding YSI Blood Glucose (BG) Results in the BG Range 70 to 180 mg/dL
Time Frame: 6 hours
|
Using samples with BG 70 mg/dL to 180 mg/dL, the Mean Absolute Value of the Differences Between BGM system readings and the YSI laboratory reference values were compared.
MAD was calculated from the sum of all|(BG meter)-(BG reference)| assessments, divided by the number of assessments.
Each evaluable sample was tested on all 6 BGMS, thus the same number of BG test results was analyzed for each BGMS intervention.
Lower MAD value indicates smaller difference between meter value and the reference value.
Higher MAD value indicates larger difference between meter value and the reference value.
|
6 hours
|
MAD Mean Absolute Value of the Difference Between Blood Glucose Meter (BGMS) Results and Corresponding YSI Blood Glucose (BG) Results in the BG Range >180 mg/dL
Time Frame: 6 hours
|
Using samples with BG >180 mg/dL, the Mean Absolute Value of the Differences Between BGM system readings and the YSI laboratory reference values was compared.
MAD was calculated from the sum of all |(BG meter)-(BG reference)| assessments, divided by the number of assessments.
Each evaluable sample was tested on all 6 BGMS, thus the same number of BG test results was analyzed for each BGMS intervention.
Lower MAD value indicates smaller difference between meter value and the reference value.
Higher MAD value indicates larger difference between meter value and the reference value.
|
6 hours
|
Standard Deviations of BGMS Differences (Between BGM Meter Readings and the YSI Laboratory Reference Values Across the BG Range of All Evaluable Samples 21 mg/dL to 496 mg/dL)
Time Frame: 6 hours
|
Variability of each meter system was determined by calculating the Standard Deviation derived from each meter's differences between Blood Glucose Meter (BGMS)results and corresponding YSI Blood Glucose (BG) results.
|
6 hours
|
Number of Subject Responses 'Strongly Agree' 'Agree' or 'Neutral' With Questionnaire Statements
Time Frame: 1 hour
|
Subjects responded to statements about meter accuracy and diabetes management.
Subject responses: 'Strongly Agree' 'Agree' 'Neutral' 'Disagree' or 'Strongly Disagree'or No Response.
□1ACCURACY HELPS 1A-with my ability to talk with my HCP.
1B-my satisfaction with my self monitoring of diabetes.
1C-with my ability to manage my diabetes.
1D-prevent low BG.
1E-understand how food/exercise affects low BG.
□2 I WOULD USE ONLY the meter and strips my insurance company pays for, even if a more accurate meter was available.
□3 I USE MY CURRENT METER BECAUSE 3A-my HCP gave it to me.
3B-my insurance company covers the strips.
3C-I think it is the most accurate meter.
□4 I WOULD SWITCH meters for a more accurate meter.
□5BEING ABLE TO APPLY MORE BLOOD IS IMPORTANT 5A-as I have wasted test strips by not having enough blood to fill the strip 5B-as this would save test strips 5C-I would switch to a meter with this feature
|
1 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Leslie J Klaff, MD, Rainier Clinical Research Center Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2012
Study Registration Dates
First Submitted
May 13, 2012
First Submitted That Met QC Criteria
June 6, 2012
First Posted (Estimate)
June 8, 2012
Study Record Updates
Last Update Posted (Estimate)
February 29, 2016
Last Update Submitted That Met QC Criteria
January 29, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- CTD-2010-009-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on Bayer G3 / Tatsu System
-
Ascensia Diabetes CareCompleted
-
Ascensia Diabetes CareCompleted
-
Adolfo FontenlaRecruiting
-
Hospital de Clinicas de Porto AlegreUnknown
-
Sun Yat-sen UniversityCompletedDiabetes Mellitus, Type 1China
-
Nanoker Research S.L.National Research Council, Spain; Horizon 2020 - European Commission; Experior; ICOA Noroeste SLPCompletedPeri-ImplantitisSpain
-
AstraZenecaCompletedUlcers | Upper GI Symptoms
-
United States Naval Medical Center, PortsmouthUnknownContraceptionUnited States
-
Boston Children's HospitalCompletedType 1 Diabetes Mellitus | Glycemic ControlUnited States
-
American University of Beirut Medical CenterCompleted